LYCOS RETRIEVER 
Merck: Merck Kgaa
built 622 days ago
Merck is a global pharmaceutical and chemical company with sales of EUR 7.2 billion in 2003, a history that began in 1668, and a future shaped by 28,300 employees in 56 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds a 74% interest and free shareholders own the remaining 26%. The former U.S. subsidiary, Merck & Co., has been completely independent of the Merck Group since 1917. For further information, please check the company Website: http:/www.merck.de
Source:
Merck is a global pharmaceutical and chemical company with sales of EUR 6.3 billion in 2006, a history that began in 1668, and a future shaped by about 35,000 employees (including Merck Serono) in 56 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.
Source:
The roots of Merck KGaA reach back into the 17th century when Friedrich Jacob Merck acquired the Angel Pharmacy in Darmstadt. In 1816, Emanuel Merck took over the pharmacy and began the production of alkaloids in its laboratory. Their mass production began in 1827. From these beginnings in the pharmacy laboratory, a pharmaceutical chemicals factory gradually developed. Today, Merck is a worldwide entrepreneurial group supplying high-quality pharmaceutical and chemical products. It is still a family owned business, with 23% traded on the Stock Market.
Source:
ANNANDALE, N.J., Dec. 23 /PRNewswire/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that Merck KGaA has obtained an option to expand its collaboration with Medarex for the anti-cancer Bispecific antibody, MDX-447. Merck has obtained the exclusive option to negotiate for worldwide licensing rights, with Medarex retaining United States rights, in return for an option fee of $1.5 million and Merck's agreement to pay fully for Phase II clinical trials of MDX-447. Merck currently has exclusive marketing rights in Europe, Medarex retains U.S. rights and the two companies share the rest of the world. MDX-447 is a Bispecific antibody, jointly created by Merck and Medarex, that targets the epidermal growth factor receptor (EGF-R), which is overexpressed in many solid tumors. MDX-447 combines a cancer targeting component provided by Merck KGaA with an immune system triggering component developed by Medarex, and is currently in Phase II clinical trial. "Merck is a global research oriented pharmaceutical company with over seven products in clinical development for treating cancer, said Donald L. Drakeman, President and CEO of Medarex.
Source:
Merck KGaA is a global pharmaceutical and chemical company with sales of EUR 5.9 billion in 2004, a history that began in 1668, and a future shaped by 28,600 employees in 54 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds a 73% interest and free shareholders own the remaining 27%. The former U.S. subsidiary, Merck & Co., has been completely independent of the Merck Group since 1917.
Source:
ZymoGenetics and Merck Serono, an affiliate of Merck KGaA, Darmstadt, Germany, are developing atacicept (formerly referred to as TACI-Ig) for the treatment of autoimmune diseases and B-cell malignancies. Atacicept contains the soluble TACI receptor that binds to the cytokines BLyS and APRIL. These cytokines are members of the tumor necrosis factor family that promote B-cell survival and autoantibody production associated with certain autoimmune diseases such as SLE. Current data indicates that levels of BLyS and APRIL are elevated in patients with rheumatoid arthritis, SLE and B-cell malignancies. Atacicept has been shown to affect several stages of B-cell development and may inhibit the survival of cells responsible for making antibodies.
Source:
MORE ABOUT
Merck Kgaa